A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer

Cancer Investigation
Thomas StinchcombeM A Socinski

Abstract

To investigate the activity of carboplatin and cetuximab in NSCLC. This was a single arm, multicenter phase II trial, and the primary objective was response rate. The overall response rate observed was 9% (95% confidence interval [CI], 3-19), the progression-free survival was 2.9 months (95% CI, 1.9-3.6), the median overall survival was 8.2 months (95% CI, 4.9-10.5), and 1-year survival rate was 33% (95% CI, 21-45). The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development.

References

Nov 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P D BonomiR Comis
Nov 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A H CalvertE Wiltshaw
Jun 1, 1995·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·D F CellaP Bonomi
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F A ShepherdJ Berille
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Nov 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G V ScagliottiUNKNOWN Italian Lung Cancer Project
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John Mendelsohn, Jose Baselga
Dec 24, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David G PfisterUNKNOWN American Society of Clinical Oncology
Jun 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Giorgio V ScagliottiFred R Hirsch
Jul 29, 2004·JAMA : the Journal of the American Medical Association·Catherine DelbaldoJean-Pierre Pignon
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Oct 26, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christiane D ThieneltKaren Kelly
Nov 23, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francisco RobertMichael Needle
Sep 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ramaswamy GovindanJay Piccirillo
Nov 23, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaPhilip Bonomi
Mar 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jun KuraiEiji Shimizu
Aug 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bert H O'NeilRichard M Goldberg
Dec 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles A ButtsFrances A Shepherd
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Mar 5, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Motoki YanoYoshitaka Fujii
Mar 14, 2008·The New England Journal of Medicine·Christine H ChungThomas A E Platts-Mills
Jul 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fred R HirschDavid R Gandara
Nov 4, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hossein BorghaeiJoseph Treat

❮ Previous
Next ❯

Citations

Nov 18, 2014·The Cochrane Database of Systematic Reviews·Zu-Yao YangJin-Ling Tang
Jun 27, 2013·International Journal of Pharmaceutical Investigation·Amit GoelJaved Ali
Dec 19, 2020·Pharmaceuticals·Diana Xochiquetzal Robledo-CadenaSara Rodríguez-Enríquez

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
M A SocinskiP J Stella
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M A SocinskiWallace Akerley
© 2022 Meta ULC. All rights reserved